However, this TMZ resistance may potentially be countered with poly(ADP-ribose) polymerase inhibitors (PARPi) [92], inhibitors of the RecQ DNA helicase WRN [18, 40, 122], and newer chemotherapeutic agents specifically designed to induce DNA damage and death of MGMT-deficient tumor cells in an MMR-independent manner [123]. Here, MRC1 is linked to neoplasm.